Development Services Now Available
On July 20, 2006, Celsis announced the acquisition of In Vitro Technologies, Inc. (IVT), a US-based provider of in vitro ADME-Tox testing products and services to the pharmaceutical and biotechnology industries. In order to leverage operational synergies, IVT’s services have been realigned under the Celsis Analytical Services group. Celsis is pleased to announce Celsis Development Services. The following development services are available to customers immediately:
ADME-Tox Services
- Drug Metabolism
- Drug-Drug Interactions
- Permeability
- Plasma Protein Binding
- Bioanalytical Services
- Absorption
- Toxicity
- Methods Development and Validation for:
- In-vivo studies
- In-vitro studies
- LC/MS Capabilities
CMC Services
- Analytical
- Analytical Methods Development and Validation for:
- Drug Substance
- Drug Product
- Stability Indicating Assays
- Analytical Characterization
- Pre-formulation and Formulation Development
- Parenterals
- Topical
- Solid Dosage Forms
Expertise with multiple forms of Drug Candidates:
- Small-molecule Compounds
- Recombinant Proteins expressed in different expression systems
- Monoclonal and Polyclonal Antibodies
- Vaccines
- Synthetic and Natural Peptides
- Gene Therapy (Plasmid DNA) Products
For more information on Celsis Development Services go to http://www.celsis.com/lab_development_services.html or contact our Celsis Laboratory Group at one of the following locations or send an E-mail to info@celsislabs.com. |
